HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

May 19, 2023

Study Completion Date

June 1, 2023

Conditions
Advanced Biliary Tract Cancer
Interventions
DRUG

OXA, 5-FU and bevacizumab plus Toripalimab

"1. concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.~ B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.~ The concomitant treatment repeat every three week, up to 6 cycles.~2. Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks."

Trial Locations (1)

100142

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University

OTHER

NCT04217954 - HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC | Biotech Hunter | Biotech Hunter